BYHEALTH reports nearly 15% decline in Q1 revenue
Demand for immune supporting products had come down from the spike last year, the company explained.
“As compared to the same period last year, where immune supporting related products were seeing strong market demand, the company’s revenue in year 2024 Q1 had shown a certain degree of decline from the high base recorded last year.”
Its same name protein powder brand BYHEALTH saw a boost in popularity in the thick of COVID-19 as the Chinese authorities had encouraged the consumption of protein for supporting the body’s immunity.
In its FY23 results, sales of BYHEALTH protein powder had surged 21.45 per cent yoy to RMB$54bn (US$750m).
However, the tide had turned early this year, as sales from this segment had dropped 17.74 per cent to RMB$15.45bn (US$213m).
The decline was uniform across its other flagship brands.
Its joint care supplement, KeyLid for example, also saw sales lowered by 2.06 per cent to RMB$3.73bn (US$51.5m)
Probiotic brand Lifespace reported one of the biggest declines as sales in mainland China dipped 29.48 per cent to RMB$1.2bn (US$1.66m).
Overseas, Lifespace’s revenue was also 5.08 per cent lower than last year to RMB$2.54bn (US$34.95 m).
While sales from offline channels was down 7.55 per cent to RMB$17.22bn (US$237.87m), those coming from online sales revenue had nosedived by 26.53 per cent to RMB$9.09bn (US$125.56m).
The subdued demand for supplements in Q1 had dragged down the company’s net profit attributable to shareholders by 29.43 per cent to RMB$726.56m (US$100.36m).
Another reason for the lower revenue, BYHEALTH said, was due to increased investment in promotional activities, the company added.
It said that year 2024 was the start of its new three-year plan, where it would focus on strengthening its technology and brand strategies in launching new scientifically backed products.
Source link
Share this article:












